Cargando…
The Reevaluation of Thrombin Time Using a Clot Waveform Analysis
Object: Although thrombin burst has attracted attention as a physiological coagulation mechanism, clinical evidence from a routine assay for it is scarce. This mechanism was therefore evaluated by a clot waveform analysis (CWA) to assess the thrombin time (TT). Material and Methods: The TT with a lo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585015/ https://www.ncbi.nlm.nih.gov/pubmed/34768360 http://dx.doi.org/10.3390/jcm10214840 |
_version_ | 1784597588407746560 |
---|---|
author | Wada, Hideo Ichikawa, Yuhuko Ezaki, Minoru Matsumoto, Takeshi Yamashita, Yoshiki Shiraki, Katsuya Shimaoka, Motomu Shimpo, Hideto |
author_facet | Wada, Hideo Ichikawa, Yuhuko Ezaki, Minoru Matsumoto, Takeshi Yamashita, Yoshiki Shiraki, Katsuya Shimaoka, Motomu Shimpo, Hideto |
author_sort | Wada, Hideo |
collection | PubMed |
description | Object: Although thrombin burst has attracted attention as a physiological coagulation mechanism, clinical evidence from a routine assay for it is scarce. This mechanism was therefore evaluated by a clot waveform analysis (CWA) to assess the thrombin time (TT). Material and Methods: The TT with a low concentration of thrombin was evaluated using a CWA. We evaluated the CWA-TT of plasma deficient in various clotting factors, calibration plasma, platelet-poor plasma (PPP), and platelet-rich plasma (PRP) obtained from healthy volunteers, patients with thrombocytopenia, and patients with malignant disease. Results: Although the TT-CWA of calibration plasma was able to be evaluated with 0.01 IU/mL of thrombin, that of FVIII-deficient plasma could not be evaluated. The peak time of CWA-TT was significantly longer, and the peak height significantly lower, in various deficient plasma, especially in FVIII-deficient plasma compared to calibration plasma. The second peak of the first derivative (1st DP-2) was detected in PPP from healthy volunteers, and was shorter and higher in PRP than in PPP. The 1st DP-2 was not detected in PPP from patients with thrombocytopenia, and the 1st DP-2 in PRP was significantly lower in patients with thrombocytopenia and significantly higher in patients with malignant disease than in healthy volunteers. Conclusion: The CWA-TT became abnormal in plasma deficient in various clotting factors, and was significantly affected by platelets, suggesting that the CWA-TT may be a useful test for hemostatic abnormalities. |
format | Online Article Text |
id | pubmed-8585015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85850152021-11-12 The Reevaluation of Thrombin Time Using a Clot Waveform Analysis Wada, Hideo Ichikawa, Yuhuko Ezaki, Minoru Matsumoto, Takeshi Yamashita, Yoshiki Shiraki, Katsuya Shimaoka, Motomu Shimpo, Hideto J Clin Med Article Object: Although thrombin burst has attracted attention as a physiological coagulation mechanism, clinical evidence from a routine assay for it is scarce. This mechanism was therefore evaluated by a clot waveform analysis (CWA) to assess the thrombin time (TT). Material and Methods: The TT with a low concentration of thrombin was evaluated using a CWA. We evaluated the CWA-TT of plasma deficient in various clotting factors, calibration plasma, platelet-poor plasma (PPP), and platelet-rich plasma (PRP) obtained from healthy volunteers, patients with thrombocytopenia, and patients with malignant disease. Results: Although the TT-CWA of calibration plasma was able to be evaluated with 0.01 IU/mL of thrombin, that of FVIII-deficient plasma could not be evaluated. The peak time of CWA-TT was significantly longer, and the peak height significantly lower, in various deficient plasma, especially in FVIII-deficient plasma compared to calibration plasma. The second peak of the first derivative (1st DP-2) was detected in PPP from healthy volunteers, and was shorter and higher in PRP than in PPP. The 1st DP-2 was not detected in PPP from patients with thrombocytopenia, and the 1st DP-2 in PRP was significantly lower in patients with thrombocytopenia and significantly higher in patients with malignant disease than in healthy volunteers. Conclusion: The CWA-TT became abnormal in plasma deficient in various clotting factors, and was significantly affected by platelets, suggesting that the CWA-TT may be a useful test for hemostatic abnormalities. MDPI 2021-10-21 /pmc/articles/PMC8585015/ /pubmed/34768360 http://dx.doi.org/10.3390/jcm10214840 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wada, Hideo Ichikawa, Yuhuko Ezaki, Minoru Matsumoto, Takeshi Yamashita, Yoshiki Shiraki, Katsuya Shimaoka, Motomu Shimpo, Hideto The Reevaluation of Thrombin Time Using a Clot Waveform Analysis |
title | The Reevaluation of Thrombin Time Using a Clot Waveform Analysis |
title_full | The Reevaluation of Thrombin Time Using a Clot Waveform Analysis |
title_fullStr | The Reevaluation of Thrombin Time Using a Clot Waveform Analysis |
title_full_unstemmed | The Reevaluation of Thrombin Time Using a Clot Waveform Analysis |
title_short | The Reevaluation of Thrombin Time Using a Clot Waveform Analysis |
title_sort | reevaluation of thrombin time using a clot waveform analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585015/ https://www.ncbi.nlm.nih.gov/pubmed/34768360 http://dx.doi.org/10.3390/jcm10214840 |
work_keys_str_mv | AT wadahideo thereevaluationofthrombintimeusingaclotwaveformanalysis AT ichikawayuhuko thereevaluationofthrombintimeusingaclotwaveformanalysis AT ezakiminoru thereevaluationofthrombintimeusingaclotwaveformanalysis AT matsumototakeshi thereevaluationofthrombintimeusingaclotwaveformanalysis AT yamashitayoshiki thereevaluationofthrombintimeusingaclotwaveformanalysis AT shirakikatsuya thereevaluationofthrombintimeusingaclotwaveformanalysis AT shimaokamotomu thereevaluationofthrombintimeusingaclotwaveformanalysis AT shimpohideto thereevaluationofthrombintimeusingaclotwaveformanalysis AT wadahideo reevaluationofthrombintimeusingaclotwaveformanalysis AT ichikawayuhuko reevaluationofthrombintimeusingaclotwaveformanalysis AT ezakiminoru reevaluationofthrombintimeusingaclotwaveformanalysis AT matsumototakeshi reevaluationofthrombintimeusingaclotwaveformanalysis AT yamashitayoshiki reevaluationofthrombintimeusingaclotwaveformanalysis AT shirakikatsuya reevaluationofthrombintimeusingaclotwaveformanalysis AT shimaokamotomu reevaluationofthrombintimeusingaclotwaveformanalysis AT shimpohideto reevaluationofthrombintimeusingaclotwaveformanalysis |